Inhibikase Therapeutics, Inc. (IKT): Nasdaq/NYSE listing notice — Inhibikase receives Nasdaq extension to July 24, 2023 to regain $1 minimum bid price compliance

Inhibikase Therapeutics, Inc.

Nasdaq granted additional 180-day period until July 24, 2023 to meet Minimum Bid Price Requirement.
Compliance requires closing bid price at least $1.00 for 10 consecutive business days.
Company previously disclosed deficiency on July 25, 2022; intends to cure via reverse stock split if needed.
Failure to demonstrate compliance by July 24, 2023 will result in Nasdaq delisting notice, with appeal rights.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Inhibikase Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 24, 2023, the Company received notice from Nasdaq indicating that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180-day period, or until July 24, 2023, to regain compliance. According to the notice from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for the market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Minimum Bid Price Requirement, and (ii) the Company

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Inhibikase Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-014226

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.